Striatal Readministration of rAAV Vectors Reveals an Immune Response Against AAV2 Capsids That Can Be Circumvented
Open Access
- 1 March 2009
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 17 (3) , 524-537
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNAHuman Gene Therapy, 2008
- Neonatal Intraperitoneal or Intravenous Injections of Recombinant Adeno-Associated Virus Type 8 Transduce Dorsal Root Ganglia and Lower Motor NeuronsHuman Gene Therapy, 2008
- Current status of gene therapy trials for Parkinson's diseaseExperimental Neurology, 2008
- Recombinant AAV Viral Vectors Pseudotyped with Viral Capsids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous SystemMolecular Therapy, 2004
- Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectorsJournal of Virology, 2004
- Immunological Aspects of Recombinant Adeno-Associated Virus Delivery to the Mammalian BrainJournal of Virology, 2002
- Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IXMolecular Therapy, 2000
- Adeno-Associated Virus-Mediated Gene Transfer to the Brain: Duration and Modulation of ExpressionHuman Gene Therapy, 1999
- Immune responses to adenovirus vectors in the nervous systemTrends in Neurosciences, 1996
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991